Compare CLDX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLDX | FSK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 1995 | 2008 |
| Metric | CLDX | FSK |
|---|---|---|
| Price | $28.86 | $11.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 11 |
| Target Price | ★ $64.00 | $12.13 |
| AVG Volume (30 Days) | 899.2K | ★ 2.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 17.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $22.33 | $9.72 |
| 52 Week High | $45.14 | $16.31 |
| Indicator | CLDX | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 59.32 |
| Support Level | $28.26 | $10.10 |
| Resistance Level | $31.83 | $11.73 |
| Average True Range (ATR) | 1.44 | 0.35 |
| MACD | 0.15 | 0.10 |
| Stochastic Oscillator | 26.35 | 57.21 |
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.